Loans and Allowance for Credit Losses: Loans and Unfunded Credit Commitments (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Receivables [Abstract] |
|
Composition of Loans at Amortized Cost Basis Broken Out by Risk-Based Segment |
The composition of loans at amortized cost basis broken out by class of financing receivable at December 31, 2022, and December 31, 2021, respectively, is presented in the following table: | | | | | | | | | | | | | | | | | December 31, | (Dollars in millions) | | 2022 | | 2021 | Global fund banking | | $ | 41,269 | | | $ | 37,958 | | Investor dependent: | | | | | Early stage | | 1,950 | | | 1,593 | | Growth stage | | 4,763 | | | 3,951 | | Total investor dependent | | 6,713 | | | 5,544 | | Cash flow dependent — SLBO | | 1,966 | | | 1,798 | | Innovation C&I | | 8,609 | | | 6,673 | | Private bank | | 10,477 | | | 8,743 | | CRE | | 2,583 | | | 2,670 | | Premium wine | | 1,158 | | | 985 | | Other C&I | | 1,019 | | | 1,257 | | Other | | 433 | | | 317 | | PPP | | 23 | | | 331 | | Total loans (1) (2) (3) | | $ | 74,250 | | | $ | 66,276 | | ACL | | (636) | | | (422) | | Net loans | | $ | 73,614 | | | $ | 65,854 | |
(1)Total loans at amortized cost is net of unearned income, deferred fees and costs and net unamortized premiums and discounts of $283 million and $250 million at December 31, 2022, and December 31, 2021, respectively. (2)Included within our total loan portfolio are credit card loans of $555 million and $583 million at December 31, 2022, and December 31, 2021, respectively. (3)Included within our total loan portfolio are construction loans of $539 million and $367 million at December 31, 2022, and December 31, 2021, respectively.
|
Credit Quality Indicators, Broken Out by Risk-Based Segments and Vintage Year |
The following tables summarize the credit quality indicators, broken out by class of financing receivable and vintage year, as of December 31, 2022, and December 31, 2021. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Term Loans by Origination Year | | | | | | | | | December 31, 2022 (Dollars in millions) | | 2022 | | 2021 | | 2020 | | 2019 | | 2018 | | Prior | | Revolving Loans | | Revolving Loans Converted to Term Loans | | Unallocated (1) | | Total | Global fund banking: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 543 | | | $ | 90 | | | $ | 55 | | | $ | 29 | | | $ | 1 | | | $ | 5 | | | $ | 40,539 | | | $ | 3 | | | $ | — | | | $ | 41,265 | | Criticized | | — | | | — | | | — | | | — | | | — | | | — | | | 4 | | | — | | | — | | | 4 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total global fund banking | | $ | 543 | | | $ | 90 | | | $ | 55 | | | $ | 29 | | | $ | 1 | | | $ | 5 | | | $ | 40,543 | | | $ | 3 | | | $ | — | | | $ | 41,269 | | | | | | | | | | | | | | | | | | | | | | | Investor dependent: | | | | | | | | | | | | | | | | | | | | | Early stage: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 910 | | | $ | 480 | | | $ | 44 | | | $ | 12 | | | $ | 1 | | | $ | — | | | $ | 182 | | | $ | — | | | $ | — | | | $ | 1,629 | | Criticized | | 130 | | | 120 | | | 18 | | | 5 | | | — | | | — | | | 31 | | | — | | | — | | | 304 | | Nonperforming | | 5 | | | 7 | | | 1 | | | 2 | | | — | | | — | | | 2 | | | — | | | — | | | 17 | | Total early stage | | $ | 1,045 | | | $ | 607 | | | $ | 63 | | | $ | 19 | | | $ | 1 | | | $ | — | | | $ | 215 | | | $ | — | | | $ | — | | | $ | 1,950 | | | | | | | | | | | | | | | | | | | | | | | Growth stage: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,358 | | | $ | 1,175 | | | $ | 283 | | | $ | 34 | | | $ | 8 | | | $ | 2 | | | $ | 300 | | | $ | 5 | | | $ | — | | | $ | 4,165 | | Criticized | | 186 | | | 233 | | | 81 | | | 5 | | | 3 | | | 3 | | | 32 | | | — | | | — | | | 543 | | Nonperforming | | 20 | | | 31 | | | — | | | — | | | — | | | — | | | 4 | | | — | | | — | | | 55 | | Total growth stage | | $ | 2,564 | | | $ | 1,439 | | | $ | 364 | | | $ | 39 | | | $ | 11 | | | $ | 5 | | | $ | 336 | | | $ | 5 | | | $ | — | | | $ | 4,763 | | | | | | | | | | | | | | | | | | | | | | | Total investor dependent | | $ | 3,609 | | | $ | 2,046 | | | $ | 427 | | | $ | 58 | | | $ | 12 | | | $ | 5 | | | $ | 551 | | | $ | 5 | | | $ | — | | | $ | 6,713 | | Cash flow dependent — SLBO: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 930 | | | $ | 550 | | | $ | 169 | | | $ | 162 | | | $ | 14 | | | $ | 19 | | | $ | 37 | | | $ | — | | | $ | — | | | $ | 1,881 | | Criticized | | 17 | | | 34 | | | 16 | | | — | | | 2 | | | 11 | | | 5 | | | — | | | — | | | 85 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total cash flow dependent — SLBO | | $ | 947 | | | $ | 584 | | | $ | 185 | | | $ | 162 | | | $ | 16 | | | $ | 30 | | | $ | 42 | | | $ | — | | | $ | — | | | $ | 1,966 | | | | | | | | | | | | | | | | | | | | | | | Innovation C&I: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,554 | | | $ | 1,309 | | | $ | 495 | | | $ | 157 | | | $ | 5 | | | $ | 35 | | | $ | 3,152 | | | $ | — | | | $ | — | | | $ | 7,707 | | Criticized | | 65 | | | 224 | | | 168 | | | 33 | | | 11 | | | — | | | 373 | | | — | | | — | | | 874 | | Nonperforming | | 7 | | | — | | | — | | | — | | | — | | | — | | | 21 | | | — | | | — | | | 28 | | Total innovation C&I | | $ | 2,626 | | | $ | 1,533 | | | $ | 663 | | | $ | 190 | | | $ | 16 | | | $ | 35 | | | $ | 3,546 | | | $ | — | | | $ | — | | | $ | 8,609 | | | | | | | | | | | | | | | | | | | | | | | Private bank: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,782 | | | $ | 2,754 | | | $ | 1,718 | | | $ | 912 | | | $ | 427 | | | $ | 978 | | | $ | 832 | | | $ | 12 | | | $ | — | | | $ | 10,415 | | Criticized | | — | | | 16 | | | — | | | 2 | | | 1 | | | 14 | | | 4 | | | — | | | — | | | 37 | | Nonperforming | | — | | | — | | | 1 | | | 2 | | | 1 | | | 20 | | | 1 | | | — | | | — | | | 25 | | Total private bank | | $ | 2,782 | | | $ | 2,770 | | | $ | 1,719 | | | $ | 916 | | | $ | 429 | | | $ | 1,012 | | | $ | 837 | | | $ | 12 | | | $ | — | | | $ | 10,477 | | | | | | | | | | | | | | | | | | | | | | | CRE | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 519 | | | $ | 276 | | | $ | 193 | | | $ | 211 | | | $ | 144 | | | $ | 802 | | | $ | 102 | | | $ | 5 | | | $ | — | | | $ | 2,252 | | Criticized | | — | | | 11 | | | 39 | | | 133 | | | 14 | | | 112 | | | 17 | | | — | | | — | | | 326 | | Nonperforming | | — | | | — | | | — | | | 5 | | | — | | | — | | | — | | | — | | | — | | | 5 | | Total CRE | | $ | 519 | | | $ | 287 | | | $ | 232 | | | $ | 349 | | | $ | 158 | | | $ | 914 | | | $ | 119 | | | $ | 5 | | | $ | — | | | $ | 2,583 | | | | | | | | | | | | | | | | | | | | | | | Premium wine: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 309 | | | $ | 209 | | | $ | 90 | | | $ | 135 | | | $ | 43 | | | $ | 135 | | | $ | 163 | | | $ | 33 | | | $ | — | | | $ | 1,117 | | Criticized | | 1 | | | 5 | | | — | | | 7 | | | 9 | | | 9 | | | 10 | | | — | | | — | | | 41 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total premium wine | | $ | 310 | | | $ | 214 | | | $ | 90 | | | $ | 142 | | | $ | 52 | | | $ | 144 | | | $ | 173 | | | $ | 33 | | | $ | — | | | $ | 1,158 | | | | | | | | | | | | | | | | | | | | | | | Other C&I | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Term Loans by Origination Year | | | | | | | | | December 31, 2022 (Dollars in millions) | | 2022 | | 2021 | | 2020 | | 2019 | | 2018 | | Prior | | Revolving Loans | | Revolving Loans Converted to Term Loans | | Unallocated (1) | | Total | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 34 | | | $ | 141 | | | $ | 156 | | | $ | 64 | | | $ | 81 | | | $ | 284 | | | $ | 207 | | | $ | 10 | | | $ | — | | | $ | 977 | | Criticized | | 2 | | | — | | | 1 | | | 4 | | | 1 | | | 22 | | | 9 | | | 1 | | | — | | | 40 | | Nonperforming | | — | | | — | | | 1 | | | — | | | — | | | 1 | | | — | | | — | | | — | | | 2 | | Total other C&I | | $ | 36 | | | $ | 141 | | | $ | 158 | | | $ | 68 | | | $ | 82 | | | $ | 307 | | | $ | 216 | | | $ | 11 | | | $ | — | | | $ | 1,019 | | | | | | | | | | | | | | | | | | | | | | | Other: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 114 | | | $ | 189 | | | $ | 148 | | | $ | 29 | | | $ | — | | | $ | — | | | $ | 9 | | | $ | 2 | | | $ | (75) | | | $ | 416 | | Criticized | | — | | | 7 | | | 2 | | | 8 | | | — | | | — | | | — | | | — | | | — | | | 17 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total other | | $ | 114 | | | $ | 196 | | | $ | 150 | | | $ | 37 | | | $ | — | | | $ | — | | | $ | 9 | | | $ | 2 | | | $ | (75) | | | $ | 433 | | | | | | | | | | | | | | | | | | | | | | | PPP: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | — | | | $ | 12 | | | $ | 3 | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 15 | | Criticized | | — | | | 3 | | | 5 | | | — | | | — | | | — | | | — | | | — | | | — | | | 8 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total PPP | | $ | — | | | $ | 15 | | | $ | 8 | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 23 | | | | | | | | | | | | | | | | | | | | | | | Total loans | | $ | 11,486 | | | $ | 7,876 | | | $ | 3,687 | | | $ | 1,951 | | | $ | 766 | | | $ | 2,452 | | | $ | 46,036 | | | $ | 71 | | | $ | (75) | | | $ | 74,250 | | | | | | | | | | | | | | | | | | | | | | |
(1)These amounts consist of fees and clearing items that have not yet been allocated at the loan level. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Term Loans by Origination Year | | | | | | | | | December 31, 2021 (Dollars in millions) | | 2021 | | 2020 | | 2019 | | 2018 | | 2017 | | Prior | | Revolving Loans | | Revolving Loans Converted to Term Loans | | Unallocated (1) | | Total | Global fund banking: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 764 | | | $ | 115 | | | $ | 36 | | | $ | 6 | | | $ | 8 | | | $ | 4 | | | $ | 36,955 | | | $ | — | | | $ | — | | | $ | 37,888 | | Criticized | | 50 | | | 18 | | | — | | | — | | | — | | | 1 | | | 1 | | | — | | | — | | | 70 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total global fund banking | | $ | 814 | | | $ | 133 | | | $ | 36 | | | $ | 6 | | | $ | 8 | | | $ | 5 | | | $ | 36,956 | | | $ | — | | | $ | — | | | $ | 37,958 | | | | | | | | | | | | | | | | | | | | | | | Investor dependent: | | | | | | | | | | | | | | | | | | | | | Early stage: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 754 | | | $ | 287 | | | $ | 122 | | | $ | 26 | | | $ | 6 | | | $ | 1 | | | $ | 171 | | | $ | — | | | $ | — | | | $ | 1,367 | | Criticized | | 64 | | | 87 | | | 30 | | | 5 | | | — | | | — | | | 29 | | | — | | | — | | | 215 | | Nonperforming | | 2 | | | 5 | | | 3 | | | — | | | — | | | — | | | 1 | | | — | | | — | | | 11 | | Total early stage | | $ | 820 | | | $ | 379 | | | $ | 155 | | | $ | 31 | | | $ | 6 | | | $ | 1 | | | $ | 201 | | | $ | — | | | $ | — | | | $ | 1,593 | | | | | | | | | | | | | | | | | | | | | | | Growth stage: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,072 | | | $ | 910 | | | $ | 265 | | | $ | 78 | | | $ | 14 | | | $ | 1 | | | $ | 286 | | | $ | 5 | | | $ | — | | | $ | 3,631 | | Criticized | | 159 | | | 85 | | | 27 | | | 6 | | | 3 | | | — | | | 34 | | | — | | | — | | | 314 | | Nonperforming | | 2 | | | — | | | 1 | | | 2 | | | — | | | — | | | 1 | | | — | | | — | | | 6 | | Total growth stage | | $ | 2,233 | | | $ | 995 | | | $ | 293 | | | $ | 86 | | | $ | 17 | | | $ | 1 | | | $ | 321 | | | $ | 5 | | | $ | — | | | $ | 3,951 | | | | | | | | | | | | | | | | | | | | | | | Total investor dependent | | $ | 3,053 | | | $ | 1,374 | | | $ | 448 | | | $ | 117 | | | $ | 23 | | | $ | 2 | | | $ | 522 | | | $ | 5 | | | $ | — | | | $ | 5,544 | | Cash flow dependent – SLBO: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 875 | | | $ | 384 | | | $ | 252 | | | $ | 72 | | | $ | 76 | | | $ | 2 | | | $ | 35 | | | $ | — | | | $ | — | | | $ | 1,696 | | Criticized | | — | | | — | | | 20 | | | 25 | | | — | | | 13 | | | 10 | | | — | | | — | | | 68 | | Nonperforming | | — | | | — | | | 12 | | | 10 | | | 7 | | | — | | | 5 | | | — | | | — | | | 34 | | Total cash flow dependent — SLBO | | $ | 875 | | | $ | 384 | | | $ | 284 | | | $ | 107 | | | $ | 83 | | | $ | 15 | | | $ | 50 | | | $ | — | | | $ | — | | | $ | 1,798 | | | | | | | | | | | | | | | | | | | | | | | Innovation C&I: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,230 | | | $ | 1,058 | | | $ | 288 | | | $ | 123 | | | $ | 58 | | | $ | — | | | $ | 2,411 | | | $ | — | | | $ | — | | | $ | 6,168 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Term Loans by Origination Year | | | | | | | | | December 31, 2021 (Dollars in millions) | | 2021 | | 2020 | | 2019 | | 2018 | | 2017 | | Prior | | Revolving Loans | | Revolving Loans Converted to Term Loans | | Unallocated (1) | | Total | Criticized | | 64 | | | 130 | | | 62 | | | 12 | | | — | | | — | | | 236 | | | — | | | — | | | 504 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | 1 | | | — | | | — | | | 1 | | Total Innovation C&I | | $ | 2,294 | | | $ | 1,188 | | | $ | 350 | | | $ | 135 | | | $ | 58 | | | $ | — | | | $ | 2,648 | | | $ | — | | | $ | — | | | $ | 6,673 | | | | | | | | | | | | | | | | | | | | | | | Private bank: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 2,952 | | | $ | 2,015 | | | $ | 1,122 | | | $ | 520 | | | $ | 432 | | | $ | 952 | | | $ | 705 | | | $ | 8 | | | $ | — | | | $ | 8,706 | | Criticized | | — | | | — | | | 2 | | | — | | | 2 | | | 9 | | | 3 | | | — | | | — | | | 16 | | Nonperforming | | — | | | — | | | 2 | | | 9 | | | — | | | 8 | | | 2 | | | — | | | — | | | 21 | | Total private bank | | $ | 2,952 | | | $ | 2,015 | | | $ | 1,126 | | | $ | 529 | | | $ | 434 | | | $ | 969 | | | $ | 710 | | | $ | 8 | | | $ | — | | | $ | 8,743 | | | | | | | | | | | | | | | | | | | | | | | CRE: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 326 | | | $ | 215 | | | $ | 344 | | | $ | 155 | | | $ | 236 | | | $ | 868 | | | $ | 110 | | | $ | 2 | | | $ | — | | | $ | 2,256 | | Criticized | | 3 | | | 39 | | | 114 | | | 37 | | | 47 | | | 139 | | | 18 | | | 12 | | | — | | | 409 | | Nonperforming | | — | | | — | | | 5 | | | — | | | — | | | — | | | — | | | — | | | — | | | 5 | | Total CRE | | $ | 329 | | | $ | 254 | | | $ | 463 | | | $ | 192 | | | $ | 283 | | | $ | 1,007 | | | $ | 128 | | | $ | 14 | | | $ | — | | | $ | 2,670 | | | | | | | | | | | | | | | | | | | | | | | Premium wine: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 217 | | | $ | 112 | | | $ | 156 | | | $ | 69 | | | $ | 71 | | | $ | 162 | | | $ | 125 | | | $ | 34 | | | $ | — | | | $ | 946 | | Criticized | | 1 | | | 7 | | | 11 | | | 9 | | | — | | | — | | | 11 | | | — | | | — | | | 39 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total Premium wine | | $ | 218 | | | $ | 119 | | | $ | 167 | | | $ | 78 | | | $ | 71 | | | $ | 162 | | | $ | 136 | | | $ | 34 | | | $ | — | | | $ | 985 | | | | | | | | | | | | | | | | | | | | | | | Other C&I: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 181 | | | $ | 175 | | | $ | 82 | | | $ | 86 | | | $ | 28 | | | $ | 301 | | | $ | 350 | | | $ | 11 | | | $ | — | | | $ | 1,214 | | Criticized | | 5 | | | 6 | | | 6 | | | 7 | | | 2 | | | — | | | 8 | | | 5 | | | — | | | 39 | | Nonperforming | | — | | | — | | | — | | | 2 | | | — | | | 1 | | | 1 | | | — | | | — | | | 4 | | Total other C&I | | $ | 186 | | | $ | 181 | | | $ | 88 | | | $ | 95 | | | $ | 30 | | | $ | 302 | | | $ | 359 | | | $ | 16 | | | $ | — | | | $ | 1,257 | | | | | | | | | | | | | | | | | | | | | | | Other: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 61 | | | $ | 144 | | | $ | 82 | | | $ | 20 | | | $ | 14 | | | $ | — | | | $ | 7 | | | $ | — | | | $ | (21) | | | $ | 307 | | Criticized | | — | | | 7 | | | 1 | | | — | | | 2 | | | — | | | — | | | — | | | — | | | 10 | | Nonperforming | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | Total other | | $ | 61 | | | $ | 151 | | | $ | 83 | | | $ | 20 | | | $ | 16 | | | $ | — | | | $ | 7 | | | $ | — | | | $ | (21) | | | $ | 317 | | | | | | | | | | | | | | | | | | | | | | | PPP: | | | | | | | | | | | | | | | | | | | | | Risk rating: | | | | | | | | | | | | | | | | | | | | | Pass | | $ | 226 | | | $ | 72 | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 298 | | Criticized | | 22 | | | 9 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | 31 | | Nonperforming | | 2 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | 2 | | Total PPP | | $ | 250 | | | $ | 81 | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 331 | | | | | | | | | | | | | | | | | | | | | | | Total loans | | $ | 11,032 | | | $ | 5,880 | | | $ | 3,045 | | | $ | 1,279 | | | $ | 1,006 | | | $ | 2,462 | | | $ | 41,516 | | | $ | 77 | | | $ | (21) | | | $ | 66,276 | | | | | | | | | | | | | | | | | | | | | | |
(1)These amounts consist of fees and clearing items that have not yet been allocated at the loan level.
|
Activity Relating to Our Allowance for Credit Losses for Loans |
The following tables summarize the activity relating to our ACL for loans for 2022, 2021 and 2020 broken out by portfolio segment: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year ended December 31, 2022 | | Beginning Balance December 31, 2021 | | | | Charge-offs | | Recoveries | | Provision (Reduction) for Loans | | Foreign Currency Translation Adjustments | | Ending Balance December 31, 2022 | (Dollars in millions) | | | | | | | | Global fund banking | | $ | 67 | | | | | $ | — | | | $ | 7 | | | $ | 36 | | | $ | — | | | $ | 110 | | Investor dependent | | 146 | | | | | (79) | | | 20 | | | 184 | | | 2 | | | $ | 273 | | Cash flow dependent and Innovation C&I | | 118 | | | | | (19) | | | 1 | | | 55 | | | — | | | $ | 155 | | Private bank | | 33 | | | | | — | | | 2 | | | 15 | | | — | | | $ | 50 | | CRE | | 36 | | | | | — | | | — | | | (11) | | | — | | | $ | 25 | | Other C&I | | 14 | | | | | (4) | | | 1 | | | 2 | | | — | | | $ | 13 | | Premium wine and other | | 8 | | | | | (1) | | | 1 | | | 7 | | | (5) | | | $ | 10 | | | | | | | | | | | | | | | | | Total ACL | | $ | 422 | | | | | $ | (103) | | | $ | 32 | | | $ | 288 | | | $ | (3) | | | $ | 636 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year ended December 31, 2021 | | Beginning Balance December 31, 2020 | | Initial Allowance on PCD Loans | | Charge-offs | | Recoveries | | Provision (Reduction) for Loans (1) | | | | Ending Balance December 31, 2021 | (Dollars in millions) | | | | | | | | Global fund banking (2) | | $ | 46 | | | $ | — | | | $ | (80) | | | $ | — | | | $ | 101 | | | | | $ | 67 | | Investor dependent | | 213 | | | — | | | (46) | | | 18 | | | (39) | | | | | 146 | | Cash flow dependent and Innovation C&I | | 125 | | | — | | | (8) | | | 6 | | | (5) | | | | | 118 | | Private bank | | 53 | | | 1 | | | (3) | | | — | | | (18) | | | | | 33 | | CRE | | — | | | 17 | | | — | | | — | | | 19 | | | | | 36 | | Other C&I | | — | | | 4 | | | — | | | — | | | 10 | | | | | 14 | | Premium wine and other | | 9 | | | — | | | (1) | | | — | | | — | | | | | 8 | | PPP | | 2 | | | — | | | — | | | — | | | (2) | | | | | — | | Total ACL | | $ | 448 | | | $ | 22 | | | $ | (138) | | | $ | 24 | | | $ | 66 | | | | | $ | 422 | |
(1)The provision for loans for the year ended December 31, 2021, includes a post-combination initial provision of $44 million related to non-PCD loans from the Boston Private acquisition. (2)Global fund banking activity for the year ended December 31, 2021, includes the impact of an $80 million charge-off related to fraudulent activity on one loan as disclosed in previous filings. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year ended December 31, 2020 | | Beginning Balance at December 31, 2019 | | Impact of Adopting ASC 326 | | Charge-offs | | Recoveries | | Provision (Reduction) for Loans | | Foreign Currency Translation Adjustments | | Ending Balance at December 31, 2020 | (Dollars in millions) | | | | | | | | Global fund banking | | $ | 107 | | | $ | (70) | | | $ | — | | | $ | — | | | $ | 9 | | | $ | — | | | $ | 46 | | Investor dependent | | 82 | | | 72 | | | (89) | | | 25 | | | 125 | | | (2) | | | 213 | | Cash flow dependent and Innovation C&I | | 81 | | | (1) | | | (11) | | | 3 | | | 53 | | | — | | | 125 | | Private bank | | 22 | | | 12 | | | (2) | | | — | | | 21 | | | — | | | 53 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Premium wine and other | | 13 | | | 12 | | | (1) | | | 1 | | | (21) | | | 5 | | | 9 | | PPP | | — | | | — | | | — | | | — | | | 2 | | | — | | | 2 | | Total ACL | | $ | 305 | | | $ | 25 | | | $ | (103) | | | $ | 29 | | | $ | 189 | | | $ | 3 | | | $ | 448 | |
|
Aging of Gross Loans, Broken out by Portfolio Segment and Class of Financing Receivable |
The following table summarizes the aging of our loans broken out by class of financing receivables as of December 31, 2022, and December 31, 2021: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (Dollars in millions) | | 30 - 59 Days Past Due | | 60 - 89 Days Past Due | | 90 or More Days Past Due | | Total Past Due | | Current | | Total | | 90 Days or More Past Due, Still Accruing Interest | December 31, 2022: | | | | | | | | | | | | | | | Global fund banking | | $ | 20 | | | $ | — | | | $ | — | | | $ | 20 | | | $ | 41,249 | | | $ | 41,269 | | | $ | — | | Investor dependent: | | | | | | | | | | | | | | | Early stage | | 11 | | | 13 | | | 2 | | | 26 | | | 1,924 | | | 1,950 | | | — | | Growth stage | | 26 | | | — | | | 3 | | | 29 | | | 4,734 | | | 4,763 | | | — | | Total investor dependent | | 37 | | | 13 | | | 5 | | | 55 | | | 6,658 | | | 6,713 | | | — | | Cash flow dependent - SLBO | | — | | | — | | | — | | | — | | | 1,966 | | | 1,966 | | | — | | Innovation C&I | | 2 | | | 1 | | | — | | | 3 | | | 8,606 | | | 8,609 | | | — | | Private bank | | 22 | | | 2 | | | 17 | | | 41 | | | 10,436 | | | 10,477 | | | 1 | | CRE | | 10 | | | 1 | | | — | | | 11 | | | 2,572 | | | 2,583 | | | — | | Premium wine | | 3 | | | — | | | — | | | 3 | | | 1,155 | | | 1,158 | | | — | | Other C&I | | 2 | | | — | | | 2 | | | 4 | | | 1,015 | | | 1,019 | | | — | | Other | | — | | | — | | | — | | | — | | | 433 | | | 433 | | | — | | PPP | | — | | | — | | | 5 | | | 5 | | | 18 | | | 23 | | | 4 | | Total loans (1) | | $ | 96 | | | $ | 17 | | | $ | 29 | | | $ | 142 | | | $ | 74,108 | | | $ | 74,250 | | | $ | 5 | | December 31, 2021: | | | | | | | | | | | | | | | Global fund banking | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 37,958 | | | $ | 37,958 | | | $ | — | | Investor dependent: | | | | | | | | | | | | | | | Early stage | | 6 | | | 5 | | | — | | | 11 | | | 1,582 | | | 1,593 | | | — | | Growth stage | | 16 | | | — | | | — | | | 16 | | | 3,935 | | | 3,951 | | | — | | Total investor dependent | | 22 | | | 5 | | | — | | | 27 | | | 5,517 | | | 5,544 | | | — | | Cash flow dependent - SLBO | | — | | | — | | | — | | | — | | | 1,798 | | | 1,798 | | | — | | Innovation C&I | | 7 | | | — | | | 7 | | | 14 | | | 6,659 | | | 6,673 | | | 7 | | Private bank | | 28 | | | 1 | | | 12 | | | 41 | | | 8,702 | | | 8,743 | | | — | | CRE | | 1 | | | — | | | — | | | 1 | | | 2,669 | | | 2,670 | | | — | | Premium wine | | 3 | | | — | | | — | | | 3 | | | 982 | | | 985 | | | — | | Other C&I | | 1 | | | 2 | | | 1 | | | 4 | | | 1,253 | | | 1,257 | | | — | | Other | | — | | | — | | | — | | | — | | | 317 | | | 317 | | | — | | PPP | | 1 | | | — | | | — | | | 1 | | | 330 | | | 331 | | | — | | Total loans | | $ | 63 | | | $ | 8 | | | $ | 20 | | | $ | 91 | | | $ | 66,185 | | | $ | 66,276 | | | $ | 7 | |
|
Nonaccrual Loans with No Allowance for Credit Loss |
The following table summarizes our nonaccrual loans with no ACL at December 31, 2022, and December 31, 2021: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | December 31, 2022 | | December 31, 2021 | (Dollars in millions) | | Nonaccrual Loans | | Nonaccrual Loans with no ACL | | Nonaccrual Loans | | Nonaccrual Loans with no ACL | | | | | | | | | | Investor dependent: | | | | | | | | | Early stage | | $ | 17 | | | $ | — | | | $ | 11 | | | $ | — | | Growth stage | | 55 | | | 3 | | | 6 | | | — | | Total investor dependent | | 72 | | | 3 | | | 17 | | | — | | Cash flow dependent - SLBO | | — | | | — | | | 34 | | | — | | Innovation C&I | | 28 | | | — | | | 1 | | | 1 | | Private bank | | 25 | | | 7 | | | 21 | | | 8 | | CRE | | 5 | | | — | | | 5 | | | — | | | | | | | | | | | Other C&I | | 2 | | | 1 | | | 4 | | | — | | | | | | | | | | | PPP | | — | | | — | | | 2 | | | — | | Total nonaccrual loans | | $ | 132 | | | $ | 11 | | | $ | 84 | | | $ | 9 | |
|
Summary of Loans Modified in Troubled Debt Restructurings ("TDRs") by Portfolio Segment and Class of Financing Receivables |
The following table summarizes our loans modified in TDRs, broken out by class of financing receivables, as of December 31, 2022 and December 31, 2021: | | | | | | | | | | | | | | | (Dollars in millions) | | December 31, 2022 | | December 31, 2021 | Loans modified in TDRs: | | | | | Investor dependent: | | | | | Early stage | | $ | 1 | | | $ | 12 | | Growth stage | | 30 | | 3 | | Total investor dependent | | 31 | | | 15 | | Cash flow dependent - SLBO | | — | | | 34 | | Innovation C&I | | 1 | | | — | | Private bank | | 24 | | | 12 | | CRE | | 33 | | | 33 | | | | | | | Other C&I | | 1 | | 2 | | Total loans modified in TDRs | | $ | 90 | | | $ | 96 | |
|
Recorded Investment in Loans Modified in TDRs |
The following table summarizes the recorded investment in loans modified in TDRs, broken out by class of financing receivables, for modifications made during 2022, 2021 and 2020: | | | | | | | | | | | | | | | | | | | | | | | Year ended December 31, | (Dollars in millions) | | 2022 | | 2021 | | 2020 | Loans modified in TDRs during the period: | | | | | | | Investor dependent: | | | | | | | Early stage | | $ | — | | | $ | 12 | | | $ | 6 | | Growth stage | | 30 | | | — | | | 26 | | Total investor dependent | | 30 | | | 12 | | | 32 | | Cash flow dependent - SLBO | | — | | | 12 | | | 22 | | Innovation C&I | | 1 | | | — | | | 1 | | Private bank | | 17 | | | 4 | | | — | | CRE | | 5 | | | 29 | | | — | | Premium wine | | — | | | — | | | 1 | | | | | | | | | | | | | | | | Total loans modified in TDRs during the period (1) | | $ | 53 | | | $ | 57 | | | $ | 56 | |
(1)There were $110 million, $6 million and $31 million of partial charge-offs during 2022, 2021 and 2020, respectively.
|
Allowance for Unfunded Commitments |
The following table summarizes the activity relating to our ACL for unfunded credit commitments for 2022, 2021 and 2020: | | | | | | | | | | | | | | | | | | | | | | | December 31, | (Dollars in millions) | | 2022 | | 2021 | | 2020 | ACL: unfunded credit commitments, beginning balance | | $ | 171 | | | $ | 121 | | | $ | 68 | | Impact of adopting ASC 326 | | — | | | — | | | 23 | | Provision for credit losses | | 133 | | | 50 | | | 30 | | Foreign currency translation adjustments | | (1) | | | — | | | — | | ACL: unfunded credit commitments, ending balance (1) | | $ | 303 | | | $ | 171 | | | $ | 121 | |
(1)The “ACL: unfunded credit commitments” is included as a component of “other liabilities” on our consolidated balance sheets. See Note 21—“Off-Balance Sheet Arrangements, Guarantees and Other Commitments” for additional disclosures related to our commitments to extend credit.
|